Renovo bet everything on a scar drug — one failed trial killed the company

Renovo Group plc was a UK biopharmaceutical company founded in 2000 as a spin-out from the University of Manchester by Dr Sharon O'Kane. Its sole focus was developing drugs to prevent or reduce scarring — a large unmet need affecting millions of patients each year after surgery, burns, and trauma. The lead candidate was Juvista (avotermin), a recombinant human TGFβ3 protein injected into wound margins at the time of surgery to promote scar-free healing.

Juvista showed promising results in early-stage and mid-stage trials, and the company was listed on the London Stock Exchange's AIM market. By early 2011, Renovo was a single-product company with about 110 employees, a market capitalisation of approximately £240 million, and its only pipeline asset was Juvista in Phase III trials. The entire business was built around this one drug succeeding.

On February 11, 2011, Renovo announced that Juvista had failed its Phase III trial — the drug did not meet its primary efficacy endpoint of improving scar appearance versus placebo. The share price collapsed 75%, falling from about 68 pence to around 17 pence, wiping out approximately £180 million in market value in a single day. Within months, all 110 employees were laid off and the company stopped all pharmaceutical development.

Renovo continued as a shell entity providing financial services and, in August 2014, renamed itself Inspired Capital plc. The Renovo name and its entire drug pipeline were abandoned. The case became a textbook example of the binary risk in biotech investing — a company that had raised tens of millions and employed over a hundred people was destroyed by a single clinical trial failure.

Renovo bet the company on Juvista; the trial missed, the stock fell 75%, all 110 staff were laid off, and the firm renamed itself.

Renovo was a single-product company: Juvista was its only drug candidate. When that one asset failed, there was nothing else to fall back on — no pipeline depth.

The company had no revenue from marketed drugs and was entirely dependent on external capital, so a Phase III failure cut off both the product pathway and investor confidence simultaneously.

Phase III wound-healing trials rely on subjective endpoints (scar appearance scored by clinicians), hard to gauge consistently — raising the risk of missing significance even with a real effect.

The company had no partnership or co-development deal to share the risk of late-stage trials. Renovo carried the full cost and full risk of Phase III alone.

A single-product biotech is a binary option on one trial. Pipeline depth or partnerships are the only hedge against the reality that most Phase III trials fail.

Renovo laid off all 110 employees within months of the trial failure. The founder, Sharon O'Kane, left the company. Renovo was renamed Inspired Capital plc in August 2014 and continued as a financial services provider, but no longer conducted pharmaceutical research or development. The case is frequently cited in biotech industry analysis as a cautionary example of the risks of single-asset clinical development.